Showing 4621-4630 of 5771 results for "".
- Bausch + Lomb Introduces Pinnacle 360 25-Gauge Scleral Fixation Forcepshttps://modernod.com/news/bausch-lomb-introduces-pinnacle-360-25-gauge-scleral-fixation-forceps/2478053/Bausch + Lomb announced the introduction of the new Pinnacle 360 25-gauge Scleral Fixation Forceps. Bausch + Lomb will feature this innovation, as well as others in the company’s retina portfolio, during the virtual American Society of Retinal Specialists (ASRS) annual meeting, July 24-26, 2020.<
- Pfizer, BioNTech’s mRNA-Based COVID-19 Vaccine Shows Promise in Second Studyhttps://modernod.com/news/pfizer-biontechs-mrna-based-covid-19-vaccine-shows-promise-in-second-study/2478049/Pfizer and BioNTech announced that the most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 neutralising titers after the second dose in an ongoing phase 1/2 study in Germany. The results, which were publ
- Synairgen’s Inhaled Interferon Beta Cuts Chance of Developing Severe COVID-19 Diseasehttps://modernod.com/news/synairgens-inhaled-interferon-beta-cuts-chance-of-developing-severe-covid-19-disease/2478043/Synairgen announced Monday that its inhaled formulation of interferon beta, dubbed SNG001, significantly reduced the chance of developing severe disease compared to placebo in hospitalized COVID-19 patients. Chief study investigator Tom Wilkinson remarked “the results confirm our belief tha
- Interim 6-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosahttps://modernod.com/news/interim-6-month-data-of-rpgr-gene-therapy-shows-significant-vision-improvement-in-patients-living-with-x-linked-retinitis-pigmentosa/2478036/The Janssen Pharmaceutical Companies of Johnson & Johnson announced 6-month data from the ongoing phase 1/2 trial of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). The interim data showed that low and intermediate doses of
- Topcon Acquires Henson Perimeter Businesshttps://modernod.com/news/topcon-acquires-henson-perimeter-business/2478033/Topcon Healthcare announced that it has acquired the Henson line of perimetry products, including the Henson 9000 and 7000, from Elektron Eye Technology (EET) of Cambridge, UK. Terms of the deal were not disclosed. The acquisitions include the transfer of a number of EET staff to To
- Novartis to Provide 15 Drugs at Zero-Profit for Treating COVID-19 Symptomshttps://modernod.com/news/novartis-to-provide-15-drugs-at-zero-profit-for-treating-covid-19-symptoms/2478027/Novartis announced Thursday that 15 generic and over-the-counter medicines from its Sandoz unit will be made available at zero-profit to treat the major symptoms of COVID-19 in low-income and lower-middle-income countries. The drugs include those to treat gastro-intestinal illness, acute respirat
- Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial in Glaucomahttps://modernod.com/news/nicox-reports-on-enrollment-progress-in-mont-blanc-phase-3-clinical-trial-in-glaucoma/2478024/Nicox SA announced that over 40 sites have been initiated in the first month of the phase 3 Mont Blanc trial, evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. NCX 470 is the company’s novel, second-generation nitric oxide (NO)-donating bimato
- COVID-19 Has Flipped the Physician Job Search to a Seller’s Market, Recruiters Sayhttps://modernod.com/news/covid-19-has-flipped-the-physician-job-search-to-a-sellers-market-recruiters-say/2478020/Job opportunities for doctors have dried up quite a bit in wake of the COVID-19 pandemic, at least in the short term, according to an annual report from physician search firm Merritt Hawkins, according to a FierceHealthcare
- AstraZeneca, IQVIA Partner to Speed Up Studies of COVID-19 Vaccine Candidatehttps://modernod.com/news/astrazeneca-iqvia-partner-to-speed-up-studies-of-covid-19-vaccine-candidate/2478022/AstraZeneca and IQVIA are teaming up to accelerate development of the UK drugmaker’s Oxford University-partnered COVID-19 vaccine candidate AZD1222, IQVIA announced Tuesday. According to the life sciences data analytics firm, the collaboration will “drive faster delivery of clin
- National Glaucoma Research Foundation Survey Reveals Patients’ Experiences and Concerns During COVID-19https://modernod.com/news/national-glaucoma-research-foundation-survey-reveals-patients-experiences-and-concerns-during-covid-19/2478017/Glaucoma Research Foundation (GRF) announced results from a survey designed to explore glaucoma patients’ experiences and concerns during the COVID-19 pandemic-related shutdowns. The survey, conducted among patients in the GRF database and suppo